Senior Medical Director
BioMarin
Senior Medical Director
BioMarin
Orphan-drug biotech focused on rare diseases
Who We Are
BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions.
Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.
Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.
About Worldwide Research and Development
From research and discovery to post-market clinical development, our R&D engine involves all bench and clinical research and the associated groups that support those endeavors. Our teams work on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with rare diseases.
Overview
BioMarin’s Clinical Science team is seeking an accomplished Senior Medical Director to serve as a senior clinical leader responsible for shaping and executing late-stage clinical development strategy for one or more assets.
This role encompasses end-to-end clinical leadership from pivotal study design through regulatory approval and lifecycle management, with accountability for scientific rigor, strategic clarity, and development decision-making as programs advance toward registration and beyond.
Leveraging deep expertise in rare disease drug development, the Senior Medical Director will lead integrated clinical development planning, direct the design and execution of registrational studies, and guide key investment and governance decisions based on emerging safety, efficacy, and benefit-risk data.
The role partners closely with colleagues in Regulatory Affairs, Clinical Operations, Biometrics, Clinical Pharmacology, Pharmacovigilance, Medical Affairs, and Commercial to ensure BioMarin’s late-stage assets are positioned to deliver differentiated value to patients and meet global regulatory expectations.
In addition to asset-level leadership, the Senior Medical Director will contribute broader portfolio-level clinical perspective, support evaluation of internal programs and external business development opportunities, and provide mentorship and leadership within the Clinical Science organization.
This position is expected to interact regularly with senior governance bodies, global health authorities, and external scientific experts, and to represent BioMarin as a thought leader in the therapeutic area.
Key Responsibilities
BioMarin Pharmaceutical focuses on developing and selling medicines for people with rare genetic diseases. It creates orphan drugs—therapies designed for small patient populations—and has a lineup of approved treatments such as Vimizim (enzyme replacement for Morquio A syndrome), Naglazyme (enzyme replacement for MPS VI), and Kuvan (a cofactor therapy for phenylketonuria). The company’s products work by supplying missing or defective enzymes or cofactors in patients’ bodies, helping to treat the underlying metabolic problems. BioMarin differentiates itself through its specialization in rare diseases, building a pipeline of product candidates across stages of development and selling primarily to specialty pharmacies and hospitals. Its goal is to provide approved, accessible treatments for patients with limited options and to grow its portfolio to cover more rare genetic conditions.
Explore more opportunities at BioMarin